|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...89101112131415161718...3031» |
- |||| Trial completion: Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - Jun 26, 2014
P2, N=978, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed
- ||||| Fluarix Quadrivalent (influenza vaccine) / GSK
Enrollment closed: An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (clinicaltrials.gov) - Jun 24, 2014
P3, N=12000, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Enrollment open: Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above (clinicaltrials.gov) - Jun 24, 2014
P1, N=196, Recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Enrollment closed: Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial initiation date: Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Enrolling by invitation --> Active, not recruiting Initiation date: Jan 2014 --> Jun 2014
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Enrollment change: Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Jan 2014 --> Jun 2014 N=80 --> 100
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Enrollment open, Enrollment change, Trial initiation date: Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Recruiting, Sponsor: University of North Carolina, Chapel Hill
N=80 --> 100 Not yet recruiting --> Recruiting | N=80 --> 100 | Initiation date: Jan 2014 --> Jun 2014
- Clinical: 4 Pillars Toolkit for Adolescent Vaccination (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=21, Active, not recruiting, Sponsor: University of Pittsburgh
- ||| Fluarix Quadrivalent (influenza vaccine) / GSK
Enrollment open: Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - Jun 17, 2014
P1, N=240, Recruiting, Sponsor: Crucell Holland BV
Not yet recruiting --> Recruiting | N=80 --> 100 | Initiation date: Jan 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- Enrollment open: Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations (clinicaltrials.gov) - Jun 4, 2014
P2, N=400, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Trial primary completion date: Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old (clinicaltrials.gov) - Jun 4, 2014
P1/2, N=672, Active, not recruiting, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Jan 2015
- ||| Enrollment closed: Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old (clinicaltrials.gov) - Jun 4, 2014
P1/2, N=672, Active, not recruiting, Sponsor: Novartis Vaccines
Trial primary completion date: Jul 2014 --> Jan 2015 Recruiting --> Active, not recruiting
- Clinical: VAX-002: Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=22, Not yet recruiting, Sponsor: Nadine Rouphael
- |||||||||| IL-YANG FLU Vaccine Prefilled Syringe INJ (influenza virus vaccine quadrivalent) - IL / Yang Pharm
New P3 trial: Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults (clinicaltrials.gov) - Jun 1, 2014
P3, N=787, Completed, Sponsor: Il-Yang Pharm. Co., Ltd.
- New P2 trial: Immunogenicity of H5N1 Vaccine Following H5N2 (clinicaltrials.gov) - Jun 1, 2014
P2, N=43, Active, not recruiting, Sponsor: PATH
- ||| Aflunov (egg-derived H5N1 vaccine with MF59) / CSL Behring
Enrollment change: Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 (clinicaltrials.gov) - Jun 1, 2014
P1/2, N=606, Completed, Sponsor: University Hospitals, Leicester
Recruiting --> Active, not recruiting N=780 --> 606
- || Aflunov (egg-derived H5N1 vaccine with MF59) / CSL Behring
Enrollment change: Heterosubtypic Immune Responses to Influenza in Older People (clinicaltrials.gov) - Jun 1, 2014
P1, N=292, Completed, Sponsor: University Hospitals, Leicester
N=780 --> 606 N=120 --> 292
- |||| Aflunov (egg-derived H5N1 vaccine with MF59) / CSL Behring
Trial completion: Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 (clinicaltrials.gov) - Jun 1, 2014
P1/2, N=606, Completed, Sponsor: University Hospitals, Leicester
N=120 --> 292 Active, not recruiting --> Completed
- ||| Aflunov (egg-derived H5N1 vaccine with MF59) / CSL Behring
Trial completion: Heterosubtypic Immune Responses to Influenza in Older People (clinicaltrials.gov) - Jun 1, 2014
P1, N=292, Completed, Sponsor: University Hospitals, Leicester
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Trial primary completion date: Respiratory Virus Outpatient Study (FLU 002 Plus) (clinicaltrials.gov) - May 29, 2014
P=N/A, N=5000, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Enrolling by invitation --> Completed Trial primary completion date: Aug 2014 --> Aug 2015
- ||| Enrollment closed: A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (clinicaltrials.gov) - May 29, 2014
P1/2, N=84, Active, not recruiting, Sponsor: Green Cross Corporation
Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Active, not recruiting
- Video: Impact of Influenza Vaccination in Pregnancy Video Education (clinicaltrials.gov) - May 28, 2014
P=N/A, N=105, Completed, Sponsor: The Cleveland Clinic
- Trial primary completion date: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant (clinicaltrials.gov) - May 28, 2014
P=N/A, N=48, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> May 2014
- Trial completion date: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant (clinicaltrials.gov) - May 28, 2014
P=N/A, N=48, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jan 2016 --> May 2014 Trial completion date: Jan 2016 --> May 2014
- Enrollment change: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant (clinicaltrials.gov) - May 28, 2014
P=N/A, N=48, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jan 2016 --> May 2014 N=60 --> 48
- ||| Enrollment closed: Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge (clinicaltrials.gov) - May 28, 2014
P1/2, N=110, Active, not recruiting, Sponsor: Immune Targeting Systems Ltd
N=60 --> 48 Recruiting --> Active, not recruiting
- Trial completion: Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant (clinicaltrials.gov) - May 28, 2014
P=N/A, N=48, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals (clinicaltrials.gov) - May 27, 2014
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment open: Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals (clinicaltrials.gov) - May 27, 2014
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion date: Combining Entertainment & Influenza Education for Pediatric Patients (clinicaltrials.gov) - May 26, 2014
P=N/A, N=51, Completed, Sponsor: Winthrop University Hospital
Not yet recruiting --> Recruiting Trial completion date: Sep 2014 --> May 2014
- Enrollment change: Combining Entertainment & Influenza Education for Pediatric Patients (clinicaltrials.gov) - May 26, 2014
P=N/A, N=51, Completed, Sponsor: Winthrop University Hospital
Trial completion date: Sep 2014 --> May 2014 N=100 --> 51
- Trial completion: Combining Entertainment & Influenza Education for Pediatric Patients (clinicaltrials.gov) - May 26, 2014
P=N/A, N=51, Completed, Sponsor: Winthrop University Hospital
N=100 --> 51 Recruiting --> Completed
- |||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Trial primary completion date: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (clinicaltrials.gov) - May 26, 2014
P3, N=10616, Recruiting, Sponsor: Novartis Vaccines
Recruiting --> Completed Trial primary completion date: May 2015 --> Sep 2015
- ||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Trial completion date: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (clinicaltrials.gov) - May 26, 2014
P3, N=10616, Recruiting, Sponsor: Novartis Vaccines
Trial primary completion date: May 2015 --> Sep 2015 Trial completion date: Dec 2015 --> Apr 2016
- ||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Enrollment change: Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (clinicaltrials.gov) - May 26, 2014
P3, N=10616, Recruiting, Sponsor: Novartis Vaccines
Trial completion date: Dec 2015 --> Apr 2016 N=14832 --> 10616
- ||| Fluarix Quadrivalent (influenza vaccine) / GSK
New P1 trial: Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - May 26, 2014
P1, N=240, Not yet recruiting, Sponsor: Crucell Holland BV
- Enrollment change: Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults (clinicaltrials.gov) - May 25, 2014
P4, N=156, Completed, Sponsor: University of British Columbia
N=14832 --> 10616 N=275 --> 156
- Enrollment change: Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children (clinicaltrials.gov) - May 25, 2014
P4, N=167, Completed, Sponsor: University of British Columbia
N=275 --> 156 N=300 --> 167
- |||| Trial primary completion date: Japanese Pediatric H5N1 Vaccine Study (clinicaltrials.gov) - May 21, 2014
P3, N=60, Completed, Sponsor: Baxter Healthcare Corporation
N=300 --> 167 Trial primary completion date: Apr 2014 --> Nov 2013
- ||| Trial completion date: Japanese Pediatric H5N1 Vaccine Study (clinicaltrials.gov) - May 21, 2014
P3, N=60, Completed, Sponsor: Baxter Healthcare Corporation
Trial primary completion date: Apr 2014 --> Nov 2013 Trial completion date: Aug 2014 --> Apr 2014
- ||||||| Trial completion: Japanese Pediatric H5N1 Vaccine Study (clinicaltrials.gov) - May 21, 2014
P3, N=60, Completed, Sponsor: Baxter Healthcare Corporation
Trial completion date: Aug 2014 --> Apr 2014 Active, not recruiting --> Completed
- oseltamivir / Generic mfg.
Trial primary completion date: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults (clinicaltrials.gov) - May 20, 2014
P=N/A, N=800, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2014
- VIS410 / Otsuka
Trial primary completion date: A Study of VIS410 to Assess Safety and Pharmacokinetics (clinicaltrials.gov) - May 20, 2014
P1, N=30, Not yet recruiting, Sponsor: Visterra, Inc.
Trial primary completion date: Sep 2014 --> Sep 2014 Trial primary completion date: Aug 2014 --> Feb 2015
- Trial primary completion date: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) (clinicaltrials.gov) - May 20, 2014
P1, N=40, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2014 --> Feb 2015 Trial primary completion date: Apr 2014 --> May 2014
- VIS410 / Otsuka
Trial initiation date: A Study of VIS410 to Assess Safety and Pharmacokinetics (clinicaltrials.gov) - May 20, 2014
P1, N=30, Not yet recruiting, Sponsor: Visterra, Inc.
Trial primary completion date: Apr 2014 --> May 2014 Initiation date: Feb 2014 --> Oct 2014
- VIS410 / Otsuka
Trial completion date: A Study of VIS410 to Assess Safety and Pharmacokinetics (clinicaltrials.gov) - May 20, 2014
P1, N=30, Not yet recruiting, Sponsor: Visterra, Inc.
Initiation date: Feb 2014 --> Oct 2014 Trial completion date: Aug 2014 --> Feb 2015
- Trial completion date: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) (clinicaltrials.gov) - May 20, 2014
P1, N=40, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Aug 2014 --> Feb 2015 Trial completion date: Apr 2014 --> May 2014
- Enrollment closed: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) (clinicaltrials.gov) - May 20, 2014
P1, N=40, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Apr 2014 --> May 2014 Recruiting --> Active, not recruiting
- |||| Enrollment open: A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (clinicaltrials.gov) - May 19, 2014
P1/2, N=84, Recruiting, Sponsor: Green Cross Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | New P4 trial: LAIV Immuno: A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children na (clinicaltrials.gov) - May 19, 2014
P4, N=500, Not yet recruiting, Sponsor: Health Protection Agency, United Kingdom